Abstract:Objective: Hematological indicators in the early stage of PD-1 inhibitor treatment may show superior predictive ability of the occurrence of immune related adverse event (irAE) compared to the pre-treatment indicators, as the immune response is modulated during the PD-1 inhibitor treatment. The objective of this study was to investigate the predictive capabilities of biomarkers in the early treatment stage for immune related thyroid dysfunction (irTD), and explore the potential predictive cytokines. Methods: Medical records and blood test results of cancer patients treated with PD-1 inhibitor at a certain medical institution were collected. Logistic regression analysis was utilized to identify the predictive factors of irTD, ROC curves were plotted and the area under the curves (AUC) was calculated. Serum samples were collected before and during early treatment phase, cytokine detection was performed to explore potential predictive cytokines. Results: A total of 264 patients were enrolled, 58 developed irTD (21.97%), including 31 patients with thyrotoxicosis and 27 with hypothyroidism. There were no significant differences in demographic characteristics, tumor types and PD-1 inhibitors between patients with and without irTD. Multivariate logistic analysis showed that anti-thyroglobulin antibody (TgAb) (OR=2.831, 95%CI: 1.077-7.443, P =0.035) and anti-thyroperoxidase antibody (TPOAb) (OR=9.565, 95%CI: 3.399-26.921, P =0.000) in the early treatment phase were independent predictive factors for irTD, the AUC of early-stage biomarkers was larger than that of pre-treatment (0.655 vs 0.571); low level of TSH at the early stage (OR=0.162, 95%CI: 0.077-0.341, P =0.000) was significantly correlated with thyrotoxicosis; female (OR=3.889, 95%CI: 1.457-10.380, P =0.007) and positive TPOAb (OR=8.678, 95%CI: 2.656-28.357, P =0.000) at the early stage were significantly correlated with hypothyroidism. The AUCs of early-stage biomarkers were larger than that of pre-treatment both in thyrotoxicosis (0.812 vs 0.637) and hypothyroidism patients (0.728 vs 0.710). The increase of IL-16 (adjusted P =0.004), IL-12p70 (adjusted P =0.014), IL-17 (adjusted P =0.014), CCL-15 (adjusted P =0.014) and IL-1a (adjusted P =0.021) in the early treatment phase were positively correlated with irTD. Conclusions: Biomarkers at the early stage of PD-1 inhibitor treatment could predict irTD, and demonstrated stronger predictive ability compared to pre-treatment biomarkers. IL-16, IL-12p70, IL-17, CCL-15 and IL-1a could serve as potential predictive biomarkers for irTD.

Quantitative mRNA expression analysis of selected genes in the patients with early-stage hypothyroidism induced by iodine-131 treatment

Radiosensitivity-related postirradiation hypothyroidism in Graves’ disease patients

The relationship between epidermal growth factor receptor mRNA expression and the efficacy of 131I treatment in hyperthyroidism patients

Prognostic Factor Analysis in 325 Patients with Graves' Disease Treated with Radioiodine Therapy.

Analysis of iodine-131-induced early thyroid hormone variations in Graves' disease.

Risk factors of early hypothyroidism after individual-dose radioiodine-131 therapy for Graves' disease

The Role of Thyroid Hormone Synthesis Gene-Related miRNAs Profiling in Structural and Functional Changes of The Thyroid Gland Induced by Excess Iodine

Correlation Between TRAb and Early Onset Hypothyroidism After 131I Treatment for Graves' Disease

Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients

Clinical observation of TGAb and TPOAb levels in early hyperthyroidism before and after ~(131)I therapy with Graves disease

Analysis of clinical features and efficacy of 131I treatment in hyperthyroid patients with thyroid nodules diagnosed by ultrasonography

Clinical study of 431 cases with hyperthyroidism after radioiodine therapy

Effects of Different Iodine Levels on the DNA Methylation of Intrinsic Apoptosis-Associated Genes and Analysis of Gene-Environment Interactions in Patients with Autoimmune Thyroiditis

Predictors of Radiation-induced Hypothyroidism in Nasopharyngeal Carcinoma Survivors after Intensity-modulated Radiotherapy

Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors

Analysis of liver function, serum lipid and blood routine in patients with differentiated thyroid cancer before radioactive iodine treatment

Changes of the mRNA expression of TBX21, GATA3, RORC, FOXP3 before and after the treatment of Graves' hyperthyroidism and Graves' ophthalmopathy

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure

The effect of 131I on apoptosis of thyrocytes in patients with Graves disease

Value of normalization analysis of thyroid scans on 131I treatment planning for Graves' disease

Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction